What Is an Orphan Disease and How Is One Defined?

An orphan disease is another name for a rare disease, one that affects only a small share of the population. The word “orphan” points to something beyond rarity, though. These are conditions drug companies once had little reason to adopt, because so few patients meant too few sales to repay the cost of research. Rare one by one doesn’t mean rare overall, either: together, rare diseases touch a large share of people worldwide.1Rare Diseases International. life with a rare disease The definition is partly a medical idea and partly a legal and economic one, and that shapes how quickly people get diagnosed and treated.

The Official US Definition

The US Food and Drug Administration defines a rare disease as one affecting fewer than 200,000 people in the United States.2U.S. Food and Drug Administration. Rare Diseases at FDA That number comes from the Orphan Drug Act, a law passed in 1983 to push companies to develop treatments for rare diseases.3PLOS Neglected Tropical Diseases. The United States Food and Drug Administration (FDA) regulatory response to combat neglected tropical diseases (NTDs): A review A 1984 amendment wrote the 200,000 figure into the law.4PLOS Neglected Tropical Diseases. The United States Food and Drug Administration (FDA) regulatory response to combat neglected tropical diseases (NTDs): A review With a US population of roughly 330 million, the cutoff works out to fewer than about 1 in 1,650 Americans.

The count measures people currently living with the condition in the US, not new cases each year. A disease can be common elsewhere in the world and still be orphan here. The count also applies to the specific condition, so a subtype of a common disease can qualify on its own.

A disease affecting more than 200,000 Americans can also qualify if there is no reasonable expectation that a drug for it would recover its costs from US sales.5PLOS Neglected Tropical Diseases. The United States Food and Drug Administration (FDA) regulatory response to combat neglected tropical diseases (NTDs): A review So the definition is really about whether the market will act, not only about headcount.6U.S. Food and Drug Administration. Drug Development for Very Rare Diseases That second route exists because a fixed number alone would miss conditions that are common but still unprofitable to treat.

The 200,000 line is a policy choice, not a medical one. Nothing biological changes between a disease affecting 199,000 people and one affecting 201,000; the number was picked as a threshold for when a market is likely too small. Because it is a legal line, a disease can move across it as populations grow, diagnosis improves, or people live longer with a condition.

Orphan status isn’t automatic for a disease. A company or sponsor asks the FDA to designate a specific drug for a specific rare condition, and the FDA checks the prevalence claim. So the 200,000 test is applied to a drug’s intended use, which is why the same disease name can appear in one designation and not in another. In everyday talk, “orphan disease” is looser than the legal term, which formally attaches to drugs and their intended uses.

One common misreading is that orphan means untreatable. The label describes how many people are affected, not whether a treatment exists. Some orphan diseases have approved drugs, while many still have none. A doctor calling your condition orphan is describing its status, not giving a prognosis.

Why It’s Called an Orphan Disease

The word began with children, not rare diseases. In 1968, pediatrician Harry Shirkey wrote that infants and children had become “therapeutic orphans” because few drug companies found it worthwhile to test medicines in them.7Elixir Solutions. The Journey of Orphan Drugs: History, Development and Costs Children weren’t rare as patients, but the market for testing drugs in them looked unattractive, so they ended up with medicines tested mostly in adults. Without trials in the group, doctors had little data to guide treatment.

Others quickly borrowed “orphan” for diseases they felt the drug industry had abandoned.8Elixir Solutions. The Journey of Orphan Drugs: History, Development and Costs Rule changes in the 1960s had also left some drugs commercially “orphaned” when demand was too small to justify making them.9News-Medical. What is an Orphan Drug? A Guide to Rare Disease Therapies The term moved easily from children to small patient groups because in both cases the neglect came from economics, not from the patients’ medical needs.

The metaphor stuck because an orphan is someone with no one responsible for their care, and that image fit diseases no company felt responsible for. It also explains why the law’s remedy was to give companies reasons to “adopt” these conditions.

Patient advocates turned the word into law. In 1982 patient groups formed a coalition asking the government for help; it became the National Organization for Rare Disorders.10Elixir Solutions. The Journey of Orphan Drugs: History, Development and Costs Their pressure led to the Orphan Drug Act, signed by President Ronald Reagan in 1983.11Elixir Solutions. The Journey of Orphan Drugs: History, Development and Costs An orphan drug is any medicine designated under that law for treating, diagnosing, or preventing a rare disease.12U.S. Food and Drug Administration. Drug Development for Very Rare Diseases The broader phrase “rare diseases” grew out of this US orphan drug debate and later spread through Europe.13PubMed. How did uncommon disorders become ‘rare diseases’? History of a boundary object

So an orphan disease is the condition, and an orphan drug is a medicine given official status for treating it. A drug can hold orphan status for one rare use and be sold for other uses too. When you see “orphan designation” in drug news or on a label, it means the drug qualified for the law’s incentives.

How Other Countries Define It

The European Union counts a disease as rare when it affects fewer than 5 in 10,000 people.14PubMed Central. Global insight into rare disease and orphan drug definitions: a systematic literature review It also adds that the disease must be life-threatening or chronically debilitating.15PubMed Central. Global insight into rare disease and orphan drug definitions: a systematic literature review That means rarity alone isn’t enough; the EU asks two questions where the US asks mainly one. A mild but uncommon condition, such as a harmless variation few people have, may count as rare in the US yet not in the EU. That is a difference in definition, not in care: doctors treat people with mild rare conditions regardless of the label.

Around the world, definitions vary a great deal. Across 1,109 organizations worldwide, researchers found 296 different definitions.16PubMed. Rare Disease Terminology and Definitions-A Systematic Global Review: Report of the ISPOR Rare Disease Special Interest Group Still, most countries do set a number: 88% use a prevalence cutoff in at least one definition.17PubMed. Rare Disease Terminology and Definitions-A Systematic Global Review: Report of the ISPOR Rare Disease Special Interest Group Those cutoffs range from 5 to 76 people per 100,000, with most between 40 and 50.18PubMed. Rare Disease Terminology and Definitions-A Systematic Global Review: Report of the ISPOR Rare Disease Special Interest Group The global average is about 40 per 100,000, or 1 in 2,500 people.19PubMed. Rare Disease Terminology and Definitions-A Systematic Global Review: Report of the ISPOR Rare Disease Special Interest Group Seriousness words like “life-threatening” show up rarely outside Europe.20PubMed. Rare Disease Terminology and Definitions-A Systematic Global Review: Report of the ISPOR Rare Disease Special Interest Group

Put side by side, the US limit of 200,000 people equals roughly 60 per 100,000, and the EU’s 5 in 10,000 equals 50 per 100,000. The two limits are close, though measured differently.

That is why a disease can be orphan in one country but not another. Some inherited conditions are more common in certain populations, and a disease near a cutoff may qualify under one definition but miss another. If you’re reading foreign sources about your condition, check which definition they use.

Rare Alone, Common Together

An estimated 3.5% to 5.9% of the world’s population lives with a rare disease.21PubMed Central. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database That’s between 263 and 446 million people worldwide.22PubMed Central. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database In the EU alone it is roughly 18 to 30 million people.23PubMed Central. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database The reason is that there are thousands of distinct rare diseases: none is big, but together they hold millions of people. Each person may be the only one with their condition their doctor has ever seen, and that drives many of the problems with diagnosis and research. The estimate is a range because many rare diseases have never been counted carefully, and some people are never diagnosed, so they don’t appear in records.

What Causes Orphan Diseases

A large share of rare diseases trace back to a change in a single gene.24Genome.gov. Rare Diseases FAQ In an analysis of 1,772 orphan diseases, 69% were linked to one gene and the rest to two or more.25Medical Xpress. Mutations in essential genes often cause rare diseases A single-gene disease arises when one gene is changed in a way that stops it from doing its job, such as making a needed protein. That differs from common conditions like heart disease, where many genes and lifestyle factors each add a little. Because one gene is responsible, a test that reads that gene can often give a clear answer, so genetic testing is often central to finding the cause.

The diseases involving two or more genes can slip past a test of a single gene. That is one reason a broad test that reads many genes at once is often used when the cause is unclear. It also helps explain why two people with similar symptoms can have different underlying genetic causes.

For families, many genetic rare diseases appear in childhood. A gene change can be inherited, but it can also arise new in one person. A new change can occur in a child of healthy parents, and the parents are often not carriers in those cases. Only testing and family history can sort out which applies, and relatives may want to ask a doctor or genetic counselor about their own risk.

Some rare diseases have nothing to do with genes. Around 20% of rare conditions are thought to have no known genetic cause.26The Resources Hub. What are some non-genetic diseases? | Resources Hub These can arise from infections, environmental exposures, or reasons still unknown.27The Resources Hub. What are some non-genetic diseases? | Resources Hub

Why Diagnosis Often Takes Years

People with a rare disease wait on average 4.7 years from first symptoms to a confirmed diagnosis.28PubMed Central. Time to diagnosis and determinants of diagnostic delays of people living with a rare disease: results of a Rare Barometer retrospective patient survey That average hides a spread: half are diagnosed within about 9 months, while a quarter wait more than 5 years.29PubMed Central. Time to diagnosis and determinants of diagnostic delays of people living with a rare disease: results of a Rare Barometer retrospective patient survey Most of the delay comes after the first doctor visit, averaging 4.3 years, versus about 5 months to seek care.30PubMed Central. Time to diagnosis and determinants of diagnostic delays of people living with a rare disease: results of a Rare Barometer retrospective patient survey Seeing more than 8 health professionals or being misdiagnosed once made long delays far more likely.31PubMed Central. Time to diagnosis and determinants of diagnostic delays of people living with a rare disease: results of a Rare Barometer retrospective patient survey In mitochondrial disease, one rare group, half of patients first got a different, wrong diagnosis.32PubMed Central. The evolution of the mitochondrial disease diagnostic odyssey

Several things stretch the wait after that first visit. A doctor sees a given rare disease very seldom, so the symptoms often look like something far more common, and that is usually the first thing considered. Many rare diseases cause symptoms in several body systems, so each specialist sees only one piece and may not connect them. Standard tests often come back normal, which can lead to reassurance rather than further searching.

Seeing many specialists can prolong things too. Each new one often starts from scratch, repeating tests and questions, and nobody may be in charge of assembling the whole picture unless the patient or a primary doctor does.

A wrong diagnosis carries its own cost. It can lead to treatments that don’t help while making the real condition seem handled, and it can stop the search, since patient and doctor both think the answer is found. If treatment for a diagnosed condition isn’t working as expected, it is reasonable to ask whether the diagnosis should be revisited.

Whole-genome testing shortens the search for many. In one large program, reading a patient’s full genome gave an answer to many who had gone without one; at one hospital center, about 46% of families got a diagnosis.33PubMed Central. Clinical utility of genome sequencing in rare diseases: lessons from a single-center study of 1,452 Korean families Testing the parents along with the patient raised the success rate from about 42% to 49%.34PubMed Central. Clinical utility of genome sequencing in rare diseases: lessons from a single-center study of 1,452 Korean families A diagnosis changed treatment in only about 1 in 5 diagnosed cases, though.35PubMed Central. Clinical utility of genome sequencing in rare diseases: lessons from a single-center study of 1,452 Korean families So a name for the condition often brings understanding and family planning information more than a new treatment.

If you suspect a rare disease, keep a written timeline of symptoms, tests, and doctors seen. Ask whether a referral to a genetics or rare disease clinic makes sense, and about genetic testing, including testing parents, if results so far are unclear. Patient groups for a suspected condition can point to experienced specialists.

Why Orphan Drugs Are Scarce and Costly

The market alone doesn’t deliver these drugs, so the law offers incentives. The Orphan Drug Act gives a drug seven years of exclusive selling rights for its rare disease use.36PubMed. Evaluating The Impact Of The Orphan Drug Act’s Seven-Year Market Exclusivity Period Countries also offer research grants, tax credits, and waived fees to help companies recover costs.37PubMed Central. Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries One estimate is that only 10% of orphan drug trials would have happened without those incentives.38PubMed Central. Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries

During the exclusivity period, the FDA generally will not approve another company’s version of the same drug for the same rare use. That gives the maker a protected stretch to earn back its costs without direct competition. Exclusivity covers the specific rare use, so it doesn’t necessarily block other drugs that work differently. The same protection has a trade-off: it lets the maker set a high price while no competitor exists.

Typical US orphan drugs cost about $219,000, versus about $13,000 for other drugs.39PubMed Central. Disentangling the Cost of Orphan Drugs Marketed in the United States Research costs must be recovered from a small number of patients.40PubMed Central. Disentangling the Cost of Orphan Drugs Marketed in the United States Development costs don’t shrink just because there are fewer patients, many orphan drugs are taken for life so the yearly price adds up over decades, and small patient numbers mean makers can’t count on volume sales to bring the price down. Orphan drugs also tend to give larger health benefits than other drugs.41PubMed Central. Orphan Drugs Offer Larger Health Gains but Less Favorable Cost-effectiveness than Non-orphan Drugs Even so, insurers and health systems face hard choices about paying for them.42PubMed Central. A systematic review of moral reasons on orphan drug reimbursement

There are other routes to treatment. Doctors and researchers test existing drugs for new rare uses, which is faster than starting from scratch.43PubMed Central. Rare Disease Drug Repurposing Patient groups help shape and recruit for trials of rare disease treatments.44PubMed Central. A rare partnership: patient community and industry collaboration to shape the impact of real-world evidence on the rare disease ecosystem A few people with one-of-a-kind gene changes have received treatments designed just for them.45PubMed. The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap

In practice, ask your doctor whether any approved or off-label drug fits your condition. If an insurer denies coverage for an orphan drug, an appeal sometimes succeeds, and drug company assistance programs may cover part of the cost. Joining a patient group can give access to trials and registries.